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Abstract
Background: Biomarkers that are validated in independent cohorts are needed to
improve risk assessment for prostate cancer (PCa).
Objective: A racially diverse cohort of men (20% African American [AA]) was used to
evaluate the association of the clinically validated 17-gene Genomic Prostate Score
(GPS) with recurrence after radical prostatectomy and adverse pathology (AP) at
surgery.
Design, setting, and participants: Biopsies from 431 men treated for National Compre-
hensive Cancer Network (NCCN) very low-, low-, or intermediate-risk PCa between
1990 and 2011 at twoUSmilitarymedical centerswere tested to validate the association
between GPS and biochemical recurrence (BCR) and to conﬁrm the association with AP.
Metastatic recurrence (MR) was also evaluated.
Outcomemeasurements and statistical analysis: Cox proportional hazardsmodels were
used for BCR and MR, and logistic regression was used for AP. Central pathology review
was performed by one uropathologist. AP was deﬁned as primary Gleason pattern 4 or
any pattern 5 and/or pT3 disease.
Results and limitations: GPS results (scale: 0–100) were obtained in 402 cases (93%);
62men (15%) experienced BCR, 5 developedmetastases, and 163 had AP.Median follow-
upwas 5.2 yr. GPS predicted time to BCR in univariable analysis (hazard ratio per 20 GPS
units [HR/20 units]: 2.9; p < 0.001) and after adjusting for NCCN risk group (HR/20 units:
2.7; p < 0.001). GPS also predicted time to metastases (HR/20 units: 3.8; p = 0.032),
although the event rate was low (n = 5). GPS was strongly associated with AP (odds ratio
per 20 GPS units: 3.3; p < 0.001), adjusted for NCCN risk group. In AA and Caucasian
men, themedianGPSwas 30.3 for both, the distributions of GPS results were similar, and
GPS was similarly predictive of outcome.
Conclusions: The association of GPS with near- and long-term clinical end points
establishes the assay as a strong independent measure of PCa aggressiveness. Tumor
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1. Introduction
Men with low-risk prostate cancer (PCa) are increasingly
counseled to consider active surveillance as a safe alternative
to immediate therapy [1]. However, clinical and pathologic
features at diagnosis do not sufficiently anticipate clinical
behavior of the tumor, and concerns about tumor heteroge-
neity and undersampling associated with needle biopsies
create doubt that biopsy findings truly reflect tumor
aggressiveness [2,3]. Validated molecular biomarkers that
provide objective measures of tumor biology and improve
risk stratification are needed [4,5]. Clinical adoption of
biomarkers requires that they (1) be analytically validated to
provide robust, reproducible results; (2) be validated to
predict clinically relevantendpoints; and (3) offer equivalent
performance across a spectrum of disease including race and
age [6–8].
This study sought to confirm the ability of a biopsy-based
17-gene assay to predict adverse pathology (AP), an
actionable near-term measure of disease aggressiveness,
and to validate its association with longer term outcomes
after radical prostatectomy (RP; ie, biochemical recurrence
[BCR]) in an independent, racially diverse cohort with
National Comprehensive Cancer Network (NCCN) clinically
very low-, low-, and intermediate-risk PCa in an equal-
access health care system [9].
2. Materials and methods
2.1. Study design
All investigators agreed to the protocol and statistical analysis plan for
this prospectively designed study of archival specimens that conformed
to Reporting Recommendations for Tumour Marker Prognostic Studies
guidelines [10]. The study was approved by institutional review boards
(IRBs) at all sites, and data were locked prior to analysis.
2.2. Study population
Eligible patients includedmen treated with RP for NCCN very low-, low-,
and intermediate-risk PCa between 1990 and 2011 at two US military
medical centers (Walter Reed National Military Medical Center
[WRNMMC] and Madigan Army Medical Center) and enrolled in the
Center for Prostate Cancer Research (CPDR) longitudinal study [9],
maintained under an IRB-approved protocol. Inclusion criteria for the
BCR end point included biopsy Gleason score (GS) 6 or 7, prostate-
speciﬁc antigen (PSA) 20 ng/ml, clinical stage T2 or lower, and RP
within 6 mo of diagnosis. Exclusion criteria included adjuvant therapy,
<1 mmbiopsy tumor length, and inadequate RNA quality. For the AP end
point, patients with biopsy GS 4 + 3 were excluded (Fig. 1).
Blinded review of aggregate tissue block availability and laboratory
data revealed that >90% of eligible WRNMMC patients treated before
2001 could not be evaluated due to unavailable biopsies, lack of residual
tumor, or inadequate RNA quality, and they were excluded prior to
database lock.
aggressiveness, as measured by GPS, and outcomes were similar in AA and Caucasian
men in this equal-access health care system.
Patient summary: Predicting outcomes in men with newly diagnosed prostate cancer is
challenging. This study demonstrates that a new molecular test, the Genomic Prostate
Score, which can be performed on a patient’s original prostate needle biopsy, can predict
the aggressiveness of the cancer and help men make decisions regarding the need for
immediate treatment of their cancer.
# 2014 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).
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Confirmed Biopsy GS 6 or 7 
(Central pathology review)
n = 431
Final evaluable population for BCR end point
n = 402
29 (7%) excluded for insufficient RNA quality
CPDR Database 1990–2011*
RP-treated patients with NCCN very low, low, and
intermediate risk
n = 864
Patients with available biopsy tissue 
n = 500 69 (14%) excluded based on central 
pathology review:
Insufficient or no tumor (n = 56)
Biopsy GS >7 (n = 13)
Evaluable population for AP end point
n = 382
13 (3%) excluded for central biopsy GS 4 + 3
7 (2%) excluded for unevaluable RP slides
Fig. 1 – REMARK diagram detailing study cohort.
* Walter Reed National Military Medical Center: 2001–2011; Madigan Army Medical Center: 1990–2011.
AP = adverse pathology; BCR = biochemical recurrence; CPDR = Center for Prostate Disease Research; GS = Gleason score, RP = radical prostatectomy;
NCCN = National Comprehensive Cancer Network; REMARK = Reporting Recommendations for Tumor Marker Prognostic Studies [10].
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2.3. Pathology
Fixedparafﬁn-embeddedbiopsyandRPspecimenswerecentrally reviewed
by one uropathologist (I.A.S.) blinded to clinical outcomes and using the
2005 International Society of Urological Pathology Consensus guidelines
[11]. Biopsy reviewwas performedblinded toRP specimen review and vice
versa. Biopsy tissue sections submitted to the Genomic Health laboratory
were manually microdissected as previously described [12,13].
2.4. Assay methods
An analytically validated 17-gene quantitative reverse transcription-
polymerase chain reaction assay provides a Genomic Prostate Score
(GPS) as a measure of tumor aggressiveness [12]. The assay is validated
to predict AP at surgery in men with clinically localized PCa [13].
All analytical methods were predeﬁned and performed as previously
described [12,13]. Expression of 12 cancer genes was normalized to ﬁve
reference genes and used to calculate the GPS (scaled from 0 to 100).
2.5. Statistical methods
All analyses were detailed in a prespeciﬁed statistical analysis plan. BCR
was deﬁned as two successive PSA levels >0.2 ng/ml [14] or initiation of
salvage therapy for rising PSA. Univariable and multivariable Cox
proportional hazards (PH) models were used to evaluate the association
of GPS with BCR-free interval (bRFI; time from biopsy to BCR) and
metastasis-free interval (time from biopsy to metastasis). Losses to
follow-up and non–cancer-related deaths were censored at the time of
the last observation.
AP was deﬁned as high-grade (primary Gleason pattern 4 or any
pattern 5) and/or non–organ-conﬁned disease (pT3). Capsular incision
(pT2+) was considered non–organ-conﬁned disease [15]. The association
of GPS with AP was evaluated using binary logistic regression models
after adjustment for biopsy GS.
For Cox PH models, the PH assumption was evaluated [16], and
linearity assumption for the predictors was assessed by Martingale
residuals [17]. GPS was treated as a continuous variable. As with the ﬁrst
validation study [13], hazard ratios (HRs) and odds ratios (ORs) for GPS
were calculated per 20 units, representing the difference between the
average GPS of the highest and lowest 25th percentiles of patients. A
p value<0.05 was considered signiﬁcant based on a likelihood ratio test.
The C-statistic was used for time to event analyses and for binary
outcomes area under the curve (AUC) for receiver operating character-
istic (ROC) curves. Analyses were performed independently by CPDR and
Genomic Health using SAS v.9.2 and SAS Enterprise Guide v.6.1 (SAS
Institute Inc., Cary, NC, USA).
3. Results
3.1. Study population
Among 864 eligible patients, 500 (57.9%) had available
biopsies; 56 (11%) were excluded for insufficient tumor and
13 (3%) for biopsy GS 8. Of the remaining 431, GPS was
obtained for 402 (93%), the final evaluable population for
BCR. Of these, 382 were evaluable for AP after excluding
patients with biopsy GS 4 + 3 (n = 13 [3%]) or unavailable RP
slides (n = 7 [2%]) (Fig. 1).
Baseline characteristics in the evaluable populationwere
representative of a contemporary cohort of patients with
low-risk PCa and similar to the unevaluable population of
462 patients except that the unevaluable population had a
higher percentage of GS 6 tumors and very low-risk/low-
risk tumors (Supplementary Table 1).Median agewas 62 yr;
the distribution of NCCN clinical risk groups was very low,
11%; low, 54%; and intermediate risk, 35%. Overall, 76%
were Caucasian and 20% African American (AA). Baseline
characteristics were similar between the two sites, except
for race and patient age (Table 1).
Median follow-up was 5.2 yr; 62 patients (15.4%) had
BCR and 5 patients had metastases. In univariable models,
diagnostic PSA, central biopsy GS, and NCCN risk group
were significantly associated with bRFI (p < 0.05); race was
not (HR: 0.77 for AA vs Caucasian; 95% confidence interval
[CI], 0.37–1.46; p = 0.42) (Supplementary Table 2).
A total of 163 patients (43%) had AP; 80 (21%) had high-
grade and 130 (34%) had non–organ-confined disease
(including 39 pT2+ cases) (Supplementary Table 3). Age,
PSA, central biopsy GS, and NCCN risk group were signifi-
cantly (p< 0.05) associated with the likelihood of AP in
univariable analysis (Supplementary Table 2).
Median GPS increased with higher NCCN risk and age,
and GPS had a modest but statistically significant correla-
tion with both (NCCN, r = 0.37, p < 0.001; age, r = 0.26,
p < 0.001). However, a broad and overlapping range of GPS
resultswas observed in all NCCN risk and age groups (Fig. 2).
3.2. Biochemical recurrence and metastasis
In the prespecified primary univariable analysis, GPS was
significantly predictive of bRFI (HR/20 GPS units: 2.93; 95%
CI, 2.03–4.15; p < 0.001). PH and linearity assumptionswere
deemed to be valid (data not shown), and the HR remained
constant over time. The association between bRFI was as
strong for menwith bRFI2 yr (HR: 2.85; 95% CI, 1.69–4.61;
p < 0.001) as those with bRFI >2 yr (HR: 3.01; 95% CI,
1.78–4.96; p < 0.001). Modifying the definition of BCR
by (1) including only men with two successive PSA levels
>0.2 ng/ml (nevents = 57), (2) including patients receiving
salvage therapy without a rise in PSA (nevents = 69), or (3)
defining bRFI based on time to the second elevated PSA
instead of the first had a minimal impact on the association
between GPS and bRFI (data not shown).
GPS was the only significant predictive factor of bRFI in
multivariable analyses after adjustment for baseline char-
acteristics (Table 2), and itwas a consistent predictor of bRFI
within various clinical subgroups (Fig. 3A). For each 20-unit
increase in GPS, the HR was 2.73 (95% CI, 1.84–3.96;
p < 0.001) adjusted for NCCN risk group and 2.65 (95% CI,
1.80–3.83; p < 0.001) in a multivariable analysis adjusted
for all significant factors from the univariable analysis.
Although there were only five metastases, GPS was
significantly predictive of metastasis-free interval (HR/20
units: 3.83; 95% CI, 1.13–12.60; p = 0.032) in univariable
analysis. The small number of events precluded multivari-
able analysis.
3.3. Analysis of the adverse pathology end point
After adjusting for central biopsy GS, GPS was significantly
associated with AP (OR/20 units: 3.23; 95% CI, 2.14–4.97;
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p < 0.001) (Table 3) and high-grade (OR/20 units: 2.60;
95% CI, 1.65–4.15; p < 0.001) and non–organ-confined
disease (OR/20 units: 3.55; 95% CI, 2.33–5.54; p < 0.001)
separately. GPS was a consistent predictor of AP within
various clinical subgroups (Fig. 3B) and remained signifi-
cantly associated with AP (OR/20 units: 2.74; p < 0.001)
after adjustment for age and NCCN risk group. GPS
remained strongly predictive of AP when cases of capsular
incision (pT2+) were excluded (OR/20 units: 3.53; 95% CI,
2.25–5.53; p < 0.001).
A subset analysis in 337 patients whose biopsy
pathology criteria (biopsy GS 3 + 3 and low volume [3 or
33% positive cores] GS 3 + 4) matched the prior clinical
validation study [13] showed that the association between
GPS and AP remained significant (OR/20 units: 2.97; 95% CI,
1.94–4.67; p < 0.001) after adjusting for biopsy GS, and after
adjustment for age and NCCN risk group (Supplementary
Table 4).
3.4. Individual genes and gene groups
The 12 cancer-related genes in the GPS are divided into four
groups, representing androgen signaling, stromal response,
cellular organization, and proliferation [13]. Downregula-
tion of androgen signaling and upregulation of stromal
response gene groups were most strongly associated with
bRFI (Fig. 4A). All four gene groups were significant
predictors of AP (Fig. 4B).
3.5. Comparisons between African American and Caucasian
patients
There was a broad range of GPS results within each racial
group. GPS distribution and median GPS results were
similar between AA (GPS median: 30.3; interquartile range
[IQR]: 23–38) and Caucasian (GPS median: 30.3; IQR:
23–40) patients (Fig. 2C). No correlation was observed
Table 1 – Distribution of baseline characteristics overall (n = 402) and by site
Characteristic Site p value*
All n = 402 MAMC
n = 254
WRNMMC
n = 148
Age at diagnosis, yr
Mean 61.0 61.8 59.5 0.002
SD 7.5 6.6 8.7
Median 62.0 62.8 59.8
Minimum 40.8 40.8 40.9
Maximum 76.2 76.2 75.4
Race, n (%)
Caucasian 305 (75.9) 205 (80.7) 100 (67.6) 0.009
African American 82 (20.4) 40 (15.7) 42 (28.4)
Other 15 (3.7) 9 (3.5) 6 (4.1)
Diagnostic PSA, ng/ml, n (%)
<4 92 (22.9) 54 (21.3) 38 (25.7) 0.548
4–9.99 273 (67.9) 175 (68.9) 98 (66.2)
10–20 37 (9.2) 25 (9.8) 12 (8.1)
Clinical T stage, n (%)
T1 276 (68.7) 174 (68.5) 102 (68.9) 0.931
T2 126 (31.3) 80 (31.5) 46 (31.1)
Biopsy Gleason score, n (%)
3 + 3 295 (73.4) 184 (72.4) 111 (75.0) 0.561
3 + 4 94 (23.4) 60 (23.6) 34 (23.0)
4 + 3 13 (3.2) 10 (3.9) 3 (2.0)
NCCN risk group, n (%)**
Very low 43 (11.0) 30 (12.1) 13 (9.0) 0.571
Low 210 (53.6) 129 (52.0) 81 (56.3)
Intermediate 139 (35.5) 89 (35.9) 50 (34.7)
Surgical Gleason score, n (%)***
3 + 3 213 (55.8) 137 (57.8) 76 (52.4) 0.117
3 + 4 89 (23.3) 47 (19.8) 42 (29.0)
Any major pattern 4 or pattern 5 80 (20.9) 53 (22.4) 27 (18.6)
Pathologic T stage, n (%)***
T2 252 (66.0) 161 (67.9) 91 (62.8) 0.430
T2+ 39 (10.2) 24 (10.1) 15 (10.3)
T3a 77 (20.2) 42 (17.7) 35 (24.1)
T3b 14 (3.7) 10 (4.2) 4 (2.8)
MAMC = Madigan Army Medical Center; NCCN = National Comprehensive Cancer Network; PSA = prostate-speciﬁc antigen; SD = standard deviation;
WRNMMC =Walter Reed National Military Medical Center.
* The p value was calculated by analysis of variance for continuous covariates, and the chi-square test or Fisher exact test was used for categorical covariates
where appropriate.
** NCCN risk category could not be assigned for 10 men.
*** Surgical Gleason score and pathologic T stage data were available for 382 men with biopsy Gleason score 3 + 3 and 3 + 4: MAMC, n = 237; WRNMMC, n = 145.
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between GPS and race (r = 0.04; p = 0.45). There were no
differences in the expression of individual genes or gene
groups between AA and Caucasian men (data not shown).
The association between GPS and bRFI or AP was similarly
strong and statistically significant in both Caucasian and AA
men in univariable analysis (bRFI HR/20 units: 2.97 vs 3.50;
AP OR/20 units: 4.05 vs 2.86, respectively) (Fig. 3).
3.6. Clinical significance
In ROC analysis of AP, incorporation of GPS improved the
AUC from 0.63 (NCCN alone) to 0.72 (GPS and NCCN)
(Supplementary Fig. 1). In the subset with biopsy GS
3 + 3 and low-volume 3 + 4 disease, AUC for NCCN alone
was 0.60 compared with 0.50 without risk factors, and it
further improved to 0.69 by adding GPS (p = 0.001)
(Supplementary Fig. 1b and 1c). Thus AUC when GPS is
combined with NCCN is improved by an additional 90%
relative to AUC with NCCN risk stratification alone.
RiskprofilesandROCanalyseswereperformedtodescribe
howGPS improves the accuracy of prediction of BCR. The risk
profile curve for predicting BCR (Supplementary Fig. 2)
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Fig. 2 – Distribution of Genomic Prostate Score (GPS) results by (A) National Comprehensive Cancer Network (NCCN) risk group, (B) age quartiles, and
(C) race. The bottom and top lines of the box are the first and third quartiles of the GPS results; the line within the box is the median GPS. The ends of
the whiskers represent the extension of 1.5T interquartile range from the first and third quartiles.
GPS = Genomic Prostate Score; NCCN = National Comprehensive Cancer Network; Q = quartile.
Table 2 – Genomic Prostate Score (GPS) predicts biochemical
recurrence after radical prostatectomy alone or with adjustment
for the clinical/pathology covariates (n = 402)
Model Variable HR 95% CI p value
1 GPS/20 units 2.93 2.03–4.15 <0.001
2* GPS/20 units 2.73 1.84–3.96 <0.001
NCCN risk group: low
vs very low
1.88 0.56–11.71 0.349
Intermediate vs very
low
2.17 0.63–13.72 0.249
3* GPS/20 units 2.65 1.80–3.83 <0.001
WRNMMC vs MAMC 0.58 0.31–1.03 0.063
NCCN risk group: low
vs very low
2.01 0.60–12.56 0.294
Intermediate vs very
low
2.41 0.69–15.21 0.187
CI = conﬁdence interval; GPS = Genomic Prostate Score; HR = hazard ratio;
MAMC = Madigan Army Medical Center; NCCN = National Comprehensive
Cancer Network; WRNMMC =Walter Reed National Military Medical
Center.
*n = 392 (NCCN risk category could not be assigned for 10 patients).
Table 3 – Genomic Prostate Score predicts adverse pathology at
radical prostatectomy with adjustment for the clinical/pathology
covariates (n = 382)
Model Variable OR 95% CI p value
1 GPS/20 units 3.23 2.14–4.97 <0.001
Biopsy Gleason score
3 + 4 vs 3 + 3
1.89 1.12–3.18 0.016
2* GPS/20 units 3.25 2.12–5.10 <0.001
NCCN risk group: low
vs very low
3.17 1.33–8.81 0.008
Intermediate vs very
low
4.52 1.81–13.03 <0.001
3* GPS/20 units 2.74 1.77–4.36 <0.001
Age at diagnosis, yr 1.06 1.02–1.09 <0.001
NCCN risk group: low
vs very low
3.44 1.43–9.65 0.005
Intermediate vs very low 5.20 2.05–15.18 <0.001
CI = conﬁdence interval; GPS = Genomic Prostate Score; MAMC = Madigan
Army Medical Center; NCCN = National Comprehensive Cancer Network;
OR = odds ratio; WRNMMC =Walter Reed National Military Medical
Center.
*n = 372 (NCCN risk category could not be assigned for 10 patients).
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Fig. 3 – (A) Univariable hazard ratios (HRs) for Genomic Prostate Score (GPS) in predicting biochemical recurrence (BCR) after radical prostatectomy
(RP) within different clinical subgroups. The size of the each box is proportional to the number of patients within that patient subgroup. The thin
horizontal lines indicate the 95% confidence interval (CI) for each HR. The solid vertical line indicates the HR for GPS for the entire cohort. The dashed
vertical line indicates a HR of 1 (no association). Due to the low number of BCR events in the subgroups of patients aged <56 yr or Walter Reed
National Military Medical Center (WRNMMC) patients, the CIs for the HR of GPS were wider and included 1. (B) Univariable odds ratios (ORs) for GPS
in predicting adverse pathology at RP within different clinical subgroups. The size of the each box is proportional to the number of patients within
that patient subgroup. The thin horizontal lines indicate the 95% CI for each OR. The solid vertical line indicates the OR of GPS for the entire cohort.
The dashed vertical line indicates an OR of 1 (no association).
CI = confidence interval; NCCN = National Comprehensive Cancer Network; MAMC = Madigan Army Medical Center; PSA = prostate-specific antigen;
Q = quartile; WRNMMC =Walter Reed National Military Medical Center.
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demonstrates a wide range of 5-yr risk of BCR as GPS
increased. Average 5-yr risk was 7.5% (95% CI, 4.0–11.0) for
men in the lowestquartile ofGPS results (GPS23) and33.6%
(95% CI, 25.3–41.9) in the highest quartile (GPS 39).
Incorporation of GPS improved the C-statistic for NCCN risk
from 0.59 (NCCN alone) to 0.68 (Supplementary Fig. 1c).
4. Discussion
The strong independent association of GPS with multiple
clinical end points—BCR and AP—establishes the assay as a
robust measure of PCa aggressiveness. This study confirms
and extends findings of the prior validation study [13]. In
both studies, using identical criteria for AP and centralized
pathology review, GPS was significantly associated with AP
after adjustment for clinical and pathologic factors, and it
was predictive of both high-grade and non–organ-confined
disease. ROC analyses from this study indicate that the
added predictive value of the GPS is comparable with that
provided by the NCCN risk category.
This study also validates the assay as a strong predictor
of both early and late BCR, which has clinical relevance
because early BCR is associated with a higher risk of
systemic recurrence, whereas late BCR suggests local
recurrence [18]. The association between GPS and metas-
tases was also statistically significant, not a surprising
finding given that genes in GPS were selected primarily
based on their association with clinical recurrence [13].
Several molecular diagnostic assays have become
available for PCa [4,5,19]. NCCN guidelines now include
these assays as an option for clinically localized PCa to
improve prediction of AP at surgery or the likelihood of BCR
and PCa-specific mortality following surgery [20]. Although
three of these assays (the 17-gene GPS assay validated here,
a 46 cell cycle gene signature, and a 22-gene assay) have
been shown to predict longer term outcomes such as BCR
and metastases, only GPS has been validated to predict AP
[19]. Growing evidence indicates that use of these assays
provides physicians with greater confidence in treatment
recommendations [21].
The appropriate use of genomic assays requires under-
standing their performance within specific patient popula-
tions. Several studies have highlightedmolecular differences
in PCa in AA and Caucasian men [22] including prevalence
of transmembrane protease, serine 2/v-ets avian erythro-
blastosis virus E26 oncogene homolog (TMPRSS2-ERG)
fusions [23] and phosphatase and tensin homolog (PTEN)
deletions [24], and gene expression patterns [25]. Studies
also suggest that increased androgen signaling is seen inAA
men [26]. In this study within an equal-access health care
system, AA and Caucasian men had similar outcomes,
similar distributions and median values for GPS, and
similar distribution of individual gene groups and genes
including the androgen gene group. These findings suggest
that the tumor biology captured by GPS is similar between
Caucasian and AA men. Importantly, GPS was an equally
strong predictor for near- and longer term outcomes for
both AA and Caucasian men.
Limitations of the study should be noted. The number of
metastatic events was small, as expected in low- and
intermediate-risk patients with a 5-yr median follow-up.
The representation of other racial groups was too low to
assess the assay’s performance in other populations. Finally,
because of the limited amount of biopsy tissue available and
[(Fig._4)TD$FIG]
Fig. 4 – Performance of gene groups and individual genes that make up the Genomic Prostate Score. (A) Univariable hazard ratios (HRs) and 95%
confidence interval for gene groups and individual genes for predicting biochemical recurrence. (B) Univariable odds ratios (ORs) and 95% CI for gene
groups and individual genes for predicting adverse pathology. Each square represents the standardized HR or OR for each individual gene or gene
group. The thin horizontal lines indicate the 95% CI for each HR or OR. Standardized HR or OR indicates the HR or OR per 1-standard deviation
increase in gene expression measured on the log scale. Standardized HR >1 or OR >1 indicates that higher expression is associated with worse
outcome.
CI = confidence interval.
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degradation of RNA with time, very low-risk and low-risk
GS 6 tumors appeared more likely to be excluded for
technical reasons. Nonetheless, the final evaluable popula-
tion remained representative of a contemporary cohort.
The strength of association between GPS and AP was
notable in the face of considerable tumor heterogeneity.
Although the impact of heterogeneity was not measured in
this study, the previously described strategy of selecting
genes predictive of outcome across spatially distinct regions
of the tumor including adjacent normal-appearing tissue
[27] likely captured an underlying field effect [28] and
contributed to the successful validation of the assay.
The robustness of theGPS assay is in part due to inclusion
of genes representing multiple, distinct biologic pathways
involved in prostate tumorigenesis. In the development
studies for the assay, we found that a test including these
four pathwayswas amore robust predictor of outcome than
genes representing any single pathway [13], an observation
consistent with the complex biology underlying the
malignant process [29].
5. Conclusions
This prospectively designed study has validated the biopsy-
based GPS as a strong, independent predictor of an
actionable near-term end point (AP) and longer term
clinical outcome (BCR) in Caucasian and AA men with very
low-, low-, or intermediate-risk PCa. This establishes GPS as
a robust measure of tumor aggressiveness that can provide
more accurate risk assessment to guide treatment decisions
for men with newly diagnosed disease.
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